EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Eliminating oncogenic RAS: back to the future at the drawing board

Candy Laura Steffen, Pelin Kaya, Elisabeth Schaffner-Reckinger, Daniel Abankwa iD

Biochemical Society Transactions · 27.02.2023 · 51 (1) · 447-456

DOI: 10.1042/bst20221343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Society Transactions, online erschienen am 23.01.2023. Verfasst von Candy Laura Steffen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RAS drug development has made enormous strides in the past ten years, with the first direct KRAS inhibitor being approved in 2021. However, despite the clinical success of covalent KRAS-G12C inhibitors, we are immediately confronted with resistances as commonly found with targeted drugs. Previously believed to be undruggable due to its lack of obvious druggable pockets, a couple of new approaches to hit this much feared oncogene have now been carved out. We here concisely review these approaches to directly target four druggable sites of RAS from various angles. Our analysis focuses on the lessons learnt during the development of allele-specific covalent and non-covalent RAS inhibitors, the potential of macromolecular binders to facilitate the discovery and validation of targetable sites on RAS and finally an outlook on a future that may engage more small molecule binders to become drugs. We foresee that the latter could happen mainly in two ways: First, non-covalent small molecule inhibitors may be derived from the development of covalent binders. Second, reversible small molecule binders could be utilized for novel targeting modalities, such as degraders of RAS. Provided that degraders eliminate RAS by recruiting differentially expressed E3-ligases, this approach could enable unprecedented tissue- or developmental stage-specific destruction of RAS with potential advantages for on-target toxicity. We conclude that novel creative ideas continue to be important to exterminate RAS in cancer and other RAS pathway-driven diseases, such as RASopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansProto-Oncogene Proteins p21(ras)OncogenesGenes, rasMutation

Stichwörter der Autor:innen

RAScancerdrug development

Substanzen

Proto-Oncogene Proteins p21(ras)Antineoplastic Agents

Autor:innen und Institutionen

  • Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.

ORCID-Profile: Daniel Abankwa

Zitieren

APA

Steffen, C. L., Kaya, P., Schaffner-Reckinger, E., & Abankwa, D. (2023). Eliminating oncogenic RAS: back to the future at the drawing board. Biochemical Society Transactions, 51(1), 447-456. https://doi.org/10.1042/bst20221343

Vancouver

Steffen CL, Kaya P, Schaffner-Reckinger E, Abankwa D. Eliminating oncogenic RAS: back to the future at the drawing board. Biochemical Society Transactions. 2023;51(1):447-456. doi:10.1042/bst20221343

BibTeX
@article{Steffen2023,
  author = {Steffen, Candy Laura and Kaya, Pelin and Schaffner-Reckinger, Elisabeth and Abankwa, Daniel},
  title = {Eliminating oncogenic RAS: back to the future at the drawing board},
  journal = {Biochemical Society Transactions},
  year = {2023},
  volume = {51},
  number = {1},
  pages = {447--456},
  doi = {10.1042/bst20221343}
}
Kostenlos starten →